ATE403867T1 - Evaluierung adjuvanshaltiger impfstoffe - Google Patents

Evaluierung adjuvanshaltiger impfstoffe

Info

Publication number
ATE403867T1
ATE403867T1 AT04739011T AT04739011T ATE403867T1 AT E403867 T1 ATE403867 T1 AT E403867T1 AT 04739011 T AT04739011 T AT 04739011T AT 04739011 T AT04739011 T AT 04739011T AT E403867 T1 ATE403867 T1 AT E403867T1
Authority
AT
Austria
Prior art keywords
antigen
solid phase
immunological activity
mixture
activity
Prior art date
Application number
AT04739011T
Other languages
English (en)
Inventor
Peter Wuertzen
Gitte Lund
Henrik Hugo Jacobi
Hans-Henrik Ipsen
Original Assignee
Alk Abello As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34276701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE403867(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alk Abello As filed Critical Alk Abello As
Application granted granted Critical
Publication of ATE403867T1 publication Critical patent/ATE403867T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT04739011T 2003-08-05 2004-07-28 Evaluierung adjuvanshaltiger impfstoffe ATE403867T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49302003P 2003-08-05 2003-08-05
DKPA200301130 2003-08-05

Publications (1)

Publication Number Publication Date
ATE403867T1 true ATE403867T1 (de) 2008-08-15

Family

ID=34276701

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04739011T ATE403867T1 (de) 2003-08-05 2004-07-28 Evaluierung adjuvanshaltiger impfstoffe

Country Status (12)

Country Link
EP (1) EP1649287B1 (de)
KR (1) KR101132439B1 (de)
CN (1) CN1829917B (de)
AT (1) ATE403867T1 (de)
AU (1) AU2004269076B2 (de)
CA (1) CA2532726C (de)
DE (1) DE602004015611D1 (de)
DK (1) DK1649287T3 (de)
ES (1) ES2310732T3 (de)
MX (1) MXPA06001382A (de)
PL (1) PL1649287T3 (de)
WO (1) WO2005022157A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006291835B2 (en) 2005-09-15 2012-04-05 Alk-Abello A/S A method for quantification of allergens
CN101351561B (zh) * 2005-11-24 2013-07-17 爱尔开-阿贝优公司 测量吸附变应原酶的酶活性的方法
CA2629923C (en) 2005-11-24 2014-10-14 Alk-Abello A/S A method of measuring enzymatic activity of adsorbed allergenic enzyme
GB0601058D0 (en) * 2006-01-19 2006-03-01 Univ Southampton Mast Cell Carboxypeptidase As A Marker For Anaphylaxis And Mastocytosis
EP2652511B8 (de) 2010-12-14 2017-06-28 GlaxoSmithKline Biologicals SA Durchflusszytometrische analayse von metallsalzadsorbierten stoffen
WO2013046226A2 (en) * 2011-08-04 2013-04-04 Serum Institute Of India Ltd. A novel quantification method for vaccines
CN109752560A (zh) * 2019-02-28 2019-05-14 艾棣维欣(苏州)生物制药有限公司 一种佐剂生物活性的检测方法
CN113009052A (zh) * 2021-02-22 2021-06-22 中国食品药品检定研究院 水痘减毒活疫苗中β-内酰胺类抗生素的检测方法
EP4387594A4 (de) * 2021-08-17 2025-06-18 Innovar Scientific, Inc. Verfahren und systeme zur bewertung und konformitätsprüfung von impfstoffen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK140815B (da) * 1975-06-10 1979-11-19 Weeke Bengt Fremgangsmåde til påvisning eller bestemmelse af antistoffer i legemsvæsker ved hjælp af kendte antigener eller til bestemmelse af antigener ved hjælp af kendte antistoffer fra legemsvæsker samt et middel til anvendelse ved udøvelse af fremgangsmåden.
SU1746318A1 (ru) * 1990-06-05 1992-07-07 Институт полиомиелита и вирусных энцефалитов Способ определени концентрации белка Е вируса клещевого энцефалита в препаратах вакцины, сорбированных на гидроокиси алюмини
CN1276093C (zh) * 2001-05-15 2006-09-20 李卫云 一种检测丙肝病毒RdRp酶的方法，和载体以及用其转化的细胞株及应用

Also Published As

Publication number Publication date
AU2004269076B2 (en) 2007-09-20
CN1829917A (zh) 2006-09-06
CA2532726C (en) 2013-03-12
DK1649287T3 (da) 2008-11-24
EP1649287A1 (de) 2006-04-26
MXPA06001382A (es) 2006-08-25
CA2532726A1 (en) 2005-03-10
DE602004015611D1 (de) 2008-09-18
KR101132439B1 (ko) 2012-03-30
PL1649287T3 (pl) 2009-04-30
WO2005022157A1 (en) 2005-03-10
EP1649287B1 (de) 2008-08-06
CN1829917B (zh) 2010-08-25
AU2004269076A1 (en) 2005-03-10
KR20060126892A (ko) 2006-12-11
HK1094036A1 (en) 2007-03-16
ES2310732T3 (es) 2009-01-16

Similar Documents

Publication Publication Date Title
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
FI960978A0 (fi) Anti-GP39-vasta-aineet ja niiden käyttö
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
CY1110557T1 (el) Αντισωματα ιντερλευκινης-10
HUP0303134A3 (en) Hiv peptides, antigens, vaccine compositions, immunoassay kits and method of detecting antibodies induced by hiv
AR094125A2 (es) Anticuerpo aislado anti il-12
BRPI9911389B8 (pt) peptídeo de antígeno de domínio ige-ch3, conjugados de peptídeo, peptídeo sintético, composição farmacêutica compreendendo os mesmos, bem como uso do referido peptídeo ou conjugado do mesmo
EP1855719A4 (de) Neutralisierende monoklonale antikörper gegen coronaviren in zusammenhang mit schwerem akutem atemwegssyndrom
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
DE602004015611D1 (de) Evaluierung adjuvanshaltiger impfstoffe
WO2003016464A3 (en) Cancer specific oligosaccharide sequences and use thereof
PT1135158E (pt) Vacinas intensificadas a base de peptidos de imunoglobulina e quimerica
ATE442439T1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
BR0011449A (pt) Método para detectar sìfilis usando antìgenos sintéticos
DE50015629D1 (de) Verwendung cd28 spezifischer monoklonaler antikörpsetzung zur behandlung von virusinfektionen
ATE445839T1 (de) Latentes tuberkulose-diagnostisches antigen und verwendungsmethode
Angel et al. CpG increases vaccine antigen-specific cell-mediated immunity when administered with hepatitis B vaccine in HIV infection
EA200700345A1 (ru) Обогащённое антитело для выявления микобактериальной инфекции, способы применения и диагностические тесты, применяющие такое антитело
Yu et al. Selection of SARS-coronavirus-specific B cell epitopes by phage peptide library screening and evaluation of the immunological effect of epitope-based peptides on mice
WO2007005627A3 (en) Tuberculosis antigen detection assays and vaccines
ATE291636T1 (de) Test-kit für tuberkulose-diagnose etc.
RU2006112203A (ru) Экспресс-тест для диагностирования болезни альцгеймера
ATE442451T1 (de) Hiv-epitope und diese enthaltende pharmazeutische zusammensetzung
WO2002014866A3 (en) Methods and universal monoclonal antibody array
DE69937258D1 (de) Genetische impstoffe mit adjuvans

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1649287

Country of ref document: EP